1. Athale UH, Stewart C, Kuttesch JF, Moghrabi A, Meyer W, Pratt C, Gajjar A, Heideman RL (2001) Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol 20:88–95
2. Bertrand R, O’Connor PM, Kerrigan D, Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 28A:743–748
3. Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM (1998) Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative pediatric branch, national cancer institute, and children’s cancer group study. Clin Cancer Res 4:357–360
4. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M (2001) A Phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 7:32–37
5. Cheng MF, Chatterjee S, Berger NA (1994) Schedule dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6:269–279